Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Manidipine 6300. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manidipine 6300 SCHEMBL247919 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL1491200 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL137617 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL6275097 | 1.00 | ADRA1A (0.71) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL1491187 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL1491189 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL28927600 | 0.99 | ADRA1A (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL247471 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL29801590 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A | |
| Manidipine 6300 SCHEMBL49368 | 0.99 | MAPT (0.70) | ADRA1AMAPTTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129271-A1 | LIPID DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-06-26 | — | — | WO | claimed |
| CN-117720457-A | Manidipine hydrochloride process impurity m-nifedipine and preparation method and application thereof | 成都大学 | 2024-03-19 | — | — | CN | claimed |
| CN-115572253-A | Synthesis process of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-115403512-A | Method for controlling key impurities of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2022-11-29 | — | — | CN | claimed |
| US-20210161868-A1 | ANTI-INFLAMMATORY THERAPY IN ARRHYTHMOGENIC CARDIOMYOPATHY (ACM) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2021-06-03 | — | — | US | claimed |
| CN-108129383-B | Preparation process of optically pure manidipine hydrochloride for treating hypertension | 青岛市市立医院 | 2021-02-12 | — | — | CN | claimed |
| CN-107837240-B | Manidipine hydrochloride tablet for treating hypertension and preparation method thereof | 佛山德芮可制药有限公司 | 2020-07-07 | — | — | CN | claimed |
| EP-3470536-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2019-04-17 | — | — | EP | claimed |
| CN-208482345-U | A kind of manidipine hydrochloride raw material blending device | 回音必集团抚州制药有限公司 | 2019-02-12 | — | — | CN | claimed |
| US-10184933-B2 | Compositions, systems and methods for gene expression noise drug screening and uses thereof | The J. David Gladstone Industries (US) | 2019-01-22 | — | — | US | claimed |
| EP-1203580-A1 | QUICKLY DISINTEGRATING SOLID PREPARATIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-08 | — | — | EP | claimed |
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-08-02 | — | — | US | claimed |
| US-20010010825-A1 | Rapidly disintegrable solid preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2001-08-02 | — | — | US | claimed |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-06-21 | — | — | US | claimed |
| EP-1100469-A1 | RAPIDLY DISINTEGRABLE SOLID PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006126-A1 | RAPIDLY DISINTEGRABLE SOLID PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-02-10 | — | — | WO | claimed |
| US-5958961-A | HYPOTENSIVE AGENTS; FDA ORANGE BOOK LISTED PATENT FOR AZILSARTAN MEDOXOMIL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5721263-A | ANGIOTENSIN II ANTAGONIST IN COMBINATION WITH DIURETIC OR CALCIUM ANTAGONIST; TREATING HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | CACNA1C 62/4885ADRA1A 18/4885MAPT 3217/4885 |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | CACNA1C 62/4885ADRA1A 18/4885MAPT 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.